Quantcast

Industry news that matters to you.  Learn more

Archives for February 2012

Salimetrics Unveils New Website

Salimetrics has completed a research friendly redesign of their company website http://www.salimetrics.com, which will improve access to information on Salimetrics’ immunoassay kits, saliva collection products, and saliva testing services. In addition, the new website offers comprehensive advice on the best methods to collect, handle, store, and ship saliva samples for biomarker analysis, along with access to white papers and references to scientific research articles involving salivary analytes.

Penn State Hershey launches Institute for Personalized Medicine

Penn State Milton S. Hershey Medical Center and Penn State College of Medicine have launched the Penn State Hershey Institute for Personalized Medicine, which will bring together faculty, resources and programs devoted to advancing the relatively new field of personalized medicine, one of the most promising frontiers in medicine.

NextGen’s New Diagnostics Company Established

NextGen Group Plc (AIM: NGG), an AIM listed company providing biomarker discovery and testing services has completed the establishment of its new diagnostics subsidiary company (NextGen Sciences Dx Inc.). The board of NextGen believes that the creation of the diagnostics business as a separate corporate entity is an important milestone in the transformation of the Group from solely providing outsourced research work to owning a portfolio of valuable intellectual property.

GeneNews’ US Partner Obtains Approval to Market ColonSentry

GeneNews Limited (TSX: GEN), a company focused on developing and commercializing blood-based biomarker tests for the early detection of diseases and personalized health management, announced that Enzo Clinical Labs, a division of Enzo Biochem, Inc. (NYSE:ENZ), has received approval from New York State’s Department of Health to market ColonSentry, a blood-based test to assess an individual’s current risk for colorectal cancer. Enzo has exclusive rights to market the ColonSentry test in the states of New York and New Jersey.

VTT Searches for Novel Biomarkers and Targets for Preventing or Treating Type 2 Diabetes

VTT Technical Research Centre of Finland is participating in two new European projects focusing on type 2 diabetes. The projects aim at identifying new therapeutic choices and strategies for preventing the disease. Focus is on obtaining information on cellular dysfunction in diabetes and the effects of changes in lifestyle. The goal includes planning individual lifestyle instructions for people at high risk of diabetes and exploiting the results in a major European health insurance system.